.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Deloitte
Medtronic
Covington
Baxter
Citi
Farmers Insurance
Colorcon
Dow
Daiichi Sankyo

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205973

« Back to Dashboard

NDA 205973 describes PERPHENAZINE, which is a drug marketed by Pharm Assoc, Ani Pharms Inc, Mylan Pharms Inc, Sandoz, Vintage Pharms, Watson Labs Inc, Wilshire Pharms Inc, Ivax Sub Teva Pharms, Mylan, Par Pharm, Sun Pharm Industries, and Watson Labs, and is included in forty-five NDAs. It is available from fourteen suppliers. Additional details are available on the PERPHENAZINE profile page.

The generic ingredient in PERPHENAZINE is amitriptyline hydrochloride; perphenazine. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amitriptyline hydrochloride; perphenazine profile page.

Summary for 205973

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Antiemetics
Antipsychotics
Formulation / Manufacturing:see details

Pharmacology for NDA: 205973

Ingredient-typePhenothiazines

Suppliers and Packaging for NDA: 205973

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PERPHENAZINE perphenazine TABLET;ORAL 205973 ANDA Wilshire Pharmaceuticals, Inc. 52536-162 52536-162-01 100 TABLET, FILM COATED in 1 BOTTLE (52536-162-01)
PERPHENAZINE perphenazine TABLET;ORAL 205973 ANDA Wilshire Pharmaceuticals, Inc. 52536-164 52536-164-01 100 TABLET, FILM COATED in 1 BOTTLE (52536-164-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Dec 17, 2015TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:Dec 17, 2015TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength8MG
Approval Date:Dec 17, 2015TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
US Army
US Department of Justice
Federal Trade Commission
Argus Health
McKinsey
AstraZeneca
Covington
Cerilliant
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot